Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 5/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21380939 | 0.80 | PTPN11 (0.45) | MGLLHTR3APARG | |
| SCHEMBL21380854 | 0.78 | BCHE (0.52) | HPGDBCHEACHEMEN1KMT2A | |
| SCHEMBL21388716 | 0.69 | KDM4E (0.43) | HPGDBCHEACHEMEN1KMT2A | |
| SCHEMBL29520225 | 0.68 | HTR3A (0.74) | BCHEACHEMGLLHTR3A | |
| SCHEMBL21380926 | 0.67 | HPGD (0.47) | HPGDBCHEACHEMEN1KMT2A | |
| SCHEMBL13363263 | 0.66 | HTR3A (0.76) | BCHEACHEMGLLHTR3A | |
| SCHEMBL21380879 | 0.65 | HPGD (0.44) | HPGDBCHEACHEMEN1KMT2A | |
| SCHEMBL21380954 | 0.63 | MEN1 (0.42) | HPGDBCHEACHEMEN1KMT2A | |
| SCHEMBL13363291 | 0.62 | PARP1 (0.56) | HPGDBCHEACHEKDM4EALDH1A1 | |
| SCHEMBL13363277 | 0.62 | HPGD (0.43) | HPGDBCHEACHEMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112368272-A | SHP2 inhibitor and application thereof | 新标立亚医疗有限公司 | 2021-02-12 | — | — | CN | claimed |
| EP-3768664-A1 | SHP2 INHIBITORS AND USES THEREOF | Synblia Therapeutics, Inc. (US) | 2021-01-27 | — | — | EP | claimed |
| WO-2019182960-A1 | SHP2 INHIBITORS AND USES THEREOF | SYNBLIA THERAPEUTICS, INC. (US) | 2019-09-26 | — | — | WO | claimed |
| CN-112368272-B | SHP2 inhibitors and uses thereof | 苏州浦合医药科技有限公司 | 2023-04-21 | — | — | CN | disclosed |
| US-20230010886-A1 | SHP2 INHIBITORS AND USES THEREOF | Suzhou Puhe BioPharma Co., Ltd. (CN) | 2023-01-12 | — | — | US | disclosed |
| CN-114502165-A | SHP2 inhibitor and application thereof | 苏州浦合医药科技有限公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2021061515-A1 | SHP2 INHIBITORS AND USES THEREOF | SYNBLIA THERAPEUTICS, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| CN-112368272-A | SHP2 inhibitor and application thereof | 新标立亚医疗有限公司 | 2021-02-12 | — | — | CN | disclosed |
| EP-3768664-A1 | SHP2 INHIBITORS AND USES THEREOF | Synblia Therapeutics, Inc. (US) | 2021-01-27 | — | — | EP | disclosed |
| US-10561655-B2 | SHP2 inhibitors and uses thereof | SYNBLIA THERAPEUTICS, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| WO-2019182960-A1 | SHP2 INHIBITORS AND USES THEREOF | SYNBLIA THERAPEUTICS, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| US-20190290649-A1 | SHP2 INHIBITORS AND USES THEREOF | Suzhou Puhe BioPharma Co., Ltd. (CN) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230010886-A1 | SHP2 INHIBITORS AND USES THEREOF | PTPN1, PTPN7, PTPN18 | HPGD 2665/4885BCHE 4811/4885ACHE 4865/4885 |
| US-20190290649-A1 | SHP2 INHIBITORS AND USES THEREOF | PTPN1, PTPN7, PTPN18 | HPGD 2665/4885BCHE 4811/4885ACHE 4865/4885 |
| US-10561655-B2 | SHP2 inhibitors and uses thereof | PTPN1, PTPN7, PTPN18 | HPGD 2665/4885BCHE 4811/4885ACHE 4865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.